[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pancreatic Cancer Drug Pipeline Analysis

August 2013 | 515 pages | ID: P84FE835CC4EN
PNS Pharma

US$ 1,800.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated with the Pancreatic Cancer disease. The information for particular drug in development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. Report also helps drug development organisation to keep track record the ongoing drug profiles being developed by their key competitor in the industry.

Following parameters for each drug profile in development phase are covered in “Pancreatic Cancer Drug Pipeline Analysis” research report:
  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • Patent Information
  • Molecular Formula
  • Pharmodynamics
  • Pharmacokinetics
  • Brand Names
  • Development Agreements
  • ATC Codes
1. DEVELOPMENT PHASE: PRECLINICAL

1.1 Overview
1.2 Drug Profile

2. DEVELOPMENT PHASE: PHASE I

2.1 Overview
2.2 Drug Profile

3. DEVELOPMENT PHASE: PHASE I/II

3.1 Overview
3.2 Drug Profile

4. DEVELOPMENT PHASE: PHASE II

4.1 Overview
4.2 Drug Profile

5. DEVELOPMENT PHASE: PHASE II/III

5.1 Overview
5.2 Drug Profile

6. DEVELOPMENT PHASE: PHASE III

6.1 Overview
6.2 Drug Profile

7. DEVELOPMENT PHASE: PREREGISTRATION

7.1 Overview
7.2 Drug Profle

Precision Biologics is developing monoclonal antibodies derived from specific tumour systems, which recognise cancer-specific immunogenic proteins (tumour-associatedantigens or TAAs). Lead antibodies from this research programme, ensituximab (an NPC1C antibody), has advanced into clinical trials. The company is also developing antibody candidates targeting TAAs 31.1 (NEO 301) and 16C3 (NEO 201)for pancreatic/colorectal cancer. NEO 201 and NEO 301 are at the pre-IND stage. Precision Biologics believes that both NEO 201 and NEO 301 monoclonal antibodies may also have diagnostic applications. Preclinical development is ongoing in the US.

The programme was in development with Neogenix Oncology. In September 2012, Neogenix Oncology sold its operational assets, including the library of vaccines, antibodies, antigens and other assets, to Precision Biologics.

The TAA 16C3 appears to be a variant of carcinoembryonic antigen-related celladhesion molecules (CEACAM), which are specifically expressed by various types ofcancers, including colon, pancreatic, stomach, lung, oesophagus, larynx, breast and ovarian tissues. Precision Biologics has shown that this target is minimally expressed innormal human tissues.

Neogenix Oncology also investigated antibody candidates targeting NPC-2 (a TAA for pancreatic cancer) and antibody candidates, Sq 1 and Sq 2, targeting squamous cell carcinoma.



More Publications